Aicaigou LogoAicaigou LogoB2B WikiIndustrial Encyclopedia

Tumor Marker Test

Updated: 2026-07-15

Overview

Tumor marker tests analyze biological substances, such as proteins, genes, or enzymes, that are often elevated in cancer patients. These markers are detected in blood, urine, or tissue samples. While no single marker is universally definitive, combinations improve diagnostic accuracy. For example, PSA screens for prostate cancer, while CA-125 is linked to ovarian cancer. Clinicians use these tests alongside imaging and biopsies to guide decisions. However, benign conditions (e.g., inflammation) may also elevate markers, necessitating cautious interpretation. Advances in genomics have introduced newer markers like circulating tumor DNA (ctDNA), enhancing precision oncology.

Key Features

脑胶质瘤分子分型检测 组织样本肿瘤分子病理基因检测中云(深圳)基因生物科技有限公司

Tumor marker tests offer several advantages: they are minimally invasive, cost-effective for screening large populations, and provide quantitative data for tracking disease progression. Multiplex panels, such as those using ELISA or PCR, allow simultaneous detection of multiple markers, improving diagnostic yield. Limitations include variable specificity (e.g., CEA is raised in colorectal cancer but also in smokers) and sensitivity (early-stage cancers may not release detectable levels). False reassurance from negative results is a risk, emphasizing the need for integrated diagnostic approaches.

商家经验真实案例 · 安全可信
小鼠d二聚体elisa试剂盒
本文介绍小鼠d二聚体elisa试剂盒的基本原理、操作步骤及结果解读,帮助研究人员准确检测小鼠样本中的d二聚体水平。

Application Areas

These tests are pivotal in oncology for three main purposes: screening high-risk individuals (e.g., AFP for liver cancer in cirrhosis patients), monitoring therapy response (declining CA-125 during ovarian cancer chemotherapy), and post-treatment surveillance (rising PSA suggesting prostate cancer recurrence). Research applications include drug development, where markers serve as surrogate endpoints in clinical trials. Emerging fields like liquid biopsy leverage tumor-derived markers for real-time cancer profiling, reducing reliance on invasive tissue sampling.

Precautions

大鼠细胞周期素D1(CyclinD1)ELISA试剂盒臻双赢肿瘤标志物检测上海双赢生物科技有限公司

Interpreting tumor markers requires understanding their clinical context. For instance, mildly elevated PSA may warrant watchful waiting rather than immediate biopsy. False positives can lead to unnecessary procedures, while false negatives delay critical interventions. Pre-analytical factors (e.g., sample handling) and inter-laboratory variability can affect results. Standardized protocols and quality control programs, such as CAP accreditation, help mitigate these issues. Patients should be counseled about the tests' limitations to avoid misinterpretation.

商家经验真实案例 · 安全可信
三菱elenessa825公斤1.0参数
本文解析三菱elenessa825公斤1.0型号的核心参数配置,包括性能特点、适用场景及同类产品对比,帮助读者快速掌握该设备的关键信息。

B2B Procurement Guide

Healthcare providers should prioritize reagents and kits from vendors with robust regulatory compliance (FDA, CE IVD) and peer-reviewed clinical validation data. Bulk purchasing agreements can reduce costs for high-volume markers like CEA or PSA. Consider automated platforms (e.g., Roche Cobas) for labs processing >100 tests/day to improve throughput. Evaluate technical support, calibration services, and turnaround times for reagent replenishment. Partner with suppliers offering customizable panels for research-oriented facilities.

Related Manufacturers